on MAAT PHARMA (isin : FR0012634822)
MaaT Pharma: New cover by HC Wainwright & Co
On April 7, 2025, MaaT Pharma, a Lyon-based biotechnology company listed on Euronext, announced that HC Wainwright & Co, a leading US investment bank, has initiated coverage of its stock. This coverage is accompanied by a Buy recommendation with a target price of €21.
HC Wainwright & Co is recognized for its international corporate finance and strategic advisory services. This move highlights the global potential of MaaT Pharma, which specializes in the development of Microbiome Ecosystem Therapies™ to improve cancer patient survival.
This new coverage adds to those already carried out by several European financial companies, thus highlighting the transatlantic enthusiasm for MaaT Pharma.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MAAT PHARMA news